Patents by Inventor Thomas F. Tedder
Thomas F. Tedder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026346Abstract: Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.Type: ApplicationFiled: September 27, 2023Publication date: January 25, 2024Inventors: Thomas F. TEDDER, Evgueni KOUNTIKOV
-
Publication number: 20240011015Abstract: Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.Type: ApplicationFiled: November 22, 2022Publication date: January 11, 2024Inventors: Thomas F. TEDDER, Evgueni KOUNTIKOV
-
Publication number: 20230295562Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: ApplicationFiled: February 7, 2023Publication date: September 21, 2023Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 11230598Abstract: Provided are methods involving combination therapy comprising administering to an individual in need thereof an antibody that preferentially depletes human B10 cells and an immune checkpoint inhibitor. Antibodies for use in the methods are also provided.Type: GrantFiled: June 14, 2019Date of Patent: January 25, 2022Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhiro Fujisawa, Jacquelyn Lykken
-
Publication number: 20200283727Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.Type: ApplicationFiled: March 20, 2020Publication date: September 10, 2020Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
-
Publication number: 20200239872Abstract: Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.Type: ApplicationFiled: March 13, 2018Publication date: July 30, 2020Applicant: Duke UniversityInventors: Thomas F. TEDDER, Evgueni KOUNTIKOV
-
Patent number: 10611999Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.Type: GrantFiled: June 5, 2018Date of Patent: April 7, 2020Assignee: Duke UniversityInventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
-
Publication number: 20190367607Abstract: Provided are methods involving combination therapy comprising administering to an individual in need thereof an antibody that preferentially depletes human B10 cells and an immune checkpoint inhibitor. Antibodies for use in the methods are also provided.Type: ApplicationFiled: June 14, 2019Publication date: December 5, 2019Applicant: Duke UniversityInventors: Thomas F. TEDDER, Yasuhiro FUJISAWA, Jacquelyn LYKKEN
-
Publication number: 20190352607Abstract: Provided are feeder cell lines that can be used to expand and differentiate B cells in vitro, a method for expanding B cells in vitro comprising culturing the B cells with the feeder cell line, and a method for producing monoclonal antibody in vitro comprising culturing a single B cell with the feeder cell line under sufficient conditions and for sufficient time to induce expansion and differentiation of the B cell into a B cell done secreting antibody.Type: ApplicationFiled: February 16, 2017Publication date: November 21, 2019Applicant: Duke UniversityInventors: Hiraku SUGA, Kathleen M. CANDANDO, Evgueni KOUNTIKOV, Masahiro KAMATA, Thomas F. TEDDER, Ayumi YOSHIZAKI, Tomomitsu MIYAGAKI
-
Publication number: 20190136185Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: ApplicationFiled: November 19, 2018Publication date: May 9, 2019Applicant: Duke UniversityInventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 10131875Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: GrantFiled: August 4, 2011Date of Patent: November 20, 2018Assignee: Duke UniversityInventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20180291340Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.Type: ApplicationFiled: June 5, 2018Publication date: October 11, 2018Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
-
Patent number: 10017739Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.Type: GrantFiled: March 12, 2013Date of Patent: July 10, 2018Assignee: DUKE UNIVERSITYInventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
-
Patent number: 9913863Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: GrantFiled: May 26, 2016Date of Patent: March 13, 2018Assignee: Duke UniversityInventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 9669057Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: GrantFiled: April 27, 2009Date of Patent: June 6, 2017Assignee: Duke UniversityInventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20170088625Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.Type: ApplicationFiled: July 13, 2016Publication date: March 30, 2017Inventors: Thomas F. Tedder, Junji Uchida, Yasuhito Hamaguchi, Jonathan C. Poe
-
Publication number: 20160375059Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: ApplicationFiled: May 26, 2016Publication date: December 29, 2016Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 9416187Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.Type: GrantFiled: May 7, 2004Date of Patent: August 16, 2016Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Jonathan C. Poe
-
Patent number: 9260530Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: GrantFiled: August 1, 2013Date of Patent: February 16, 2016Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Patent number: 8734792Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: GrantFiled: May 9, 2012Date of Patent: May 27, 2014Assignee: Duke UniversityInventor: Thomas F. Tedder